New hope for kids with tough cancers: testing a powerful drug combo
NCT ID NCT03585465
Summary
This trial is testing whether adding an immunotherapy drug called nivolumab to a specific low-dose chemotherapy regimen can help control cancer in children and teenagers whose solid tumors have come back or didn't respond to standard treatments. The study first checked if the combination was safe, and is now comparing how well the chemotherapy works with and without nivolumab. It aims to find a new treatment option for young patients who have run out of other effective therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard (IHOPe)
Lyon, France
-
Centre Oscar Lambret
Lille, France
-
Cliniques Universitaires Saint-Luc (CUSL)
Brussels, Belgium
-
Hôpital La Timone, AP-HM
Marseille, France
-
Hôpital Mère-Enfant, CHU Nantes
Nantes, France
-
Hôpital d'Enfants - CHRU Nancy
Nancy, France
-
Hôpital de Hautepierre, CHRU Strasbourg
Strasbourg, France
-
Hôpital des Enfants - CHU Toulouse
Toulouse, France
-
Institut Curie
Paris, France
-
University Hospital Ghent
Ghent, Belgium
-
University Hospital Leuven
Leuven, Belgium
Conditions
Explore the condition pages connected to this study.